RxDoctor Payments Data

Joseph Gorvetzian

Albuquerque, NMNPI 1669432431

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,079 of the $3,527 with a category attached, or 87.3%. 15 manufacturers reported payments, led by AbbVie at 34.2% of the total. Reporting peaked in 2019 at $1,102 and has fallen 77.2% since, to $251 in 2025.

$3,527in general payments, 2019–2025

Across 129 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$739
  • Merck$458
  • Gilead$294
  • Viiv Healthcare Company$251
  • Integra Lifesciences Corporation$169
  • plus $410 from 9 others

What the payments were for

  • Food & beverage$3,07987%
  • Education$44813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →